Muscle tightness adverse event reports that record this term

Kind of term: MedDRA preferred term

What a report is

A report is not proof that the drug was the cause of the event.

FDA says:

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview, section "Responsible use of the data". The site read the page on 2 Oct 2026. The data have the reports that FDA received through 30 Jun 2026.

FDA also says:

There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event. The information in these reports has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of these events.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.
Source: openFDA, Response of the drug event API (meta.disclaimer). The site read the page on 2 Oct 2026.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

Reports on file

From January 2004 to June 2026, FDA received 15,905 adverse event reports that record the MedDRA preferred term Muscle tightness. The person who codes a report selects the term that agrees best with the description of the reporter.

FDA received 761 reports in the 12 months to June 2026 and 712 in the 12 months before. FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

By reports in the 12 months to June 2026, this term was number 756 of 1,436 reaction terms with a page. Of the 1,332,454 drug reports that FDA received in the 12 months to June 2026, 761 (0.1%) record this term. Reports for female patients were 63.2% of the reports that record this term and 52.7% of all drug reports.

The number of people who use the product is not in the data. A count is not a rate.

MedDRA

The Medical Dictionary for Regulatory Activities. The person who codes a report selects the preferred term that agrees best with the description of the reporter. FDA does not publish the description.

Data version

openFDA FAERS release of 29 Oct 2026. Reports received through 30 Jun 2026.

Drugs in these reports

The table has the 143 drug pages with 25 or more reports that record this term. The rows are in order of name. A drug page with fewer reports for this term is not in the table. The counts are the counts that the site keeps for each reaction term, and a count can be lower than the count of FDA.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Drugs that the reports with the term Muscle tightness name as a suspect product, in order of name
Drug	Class	Reports with this term
Abilify	Atypical antipsychotic	151
Actemra	Interleukin-6 receptor antagonist	67
Aimovig		50
Alemtuzumab	CD52-directed cytolytic antibody	41
Ambrisentan	Endothelin receptor antagonist	25
Amlodipine	Calcium channel blocker	119
Ampyra	Potassium channel blocker	160
Anastrozole	Aromatase inhibitor	30
Aripiprazole	Atypical antipsychotic	40
Ativan	Benzodiazepine	32
Atorvastatin		96
Aubagio	Pyrimidine synthesis inhibitor	78
Avonex	Interferon beta	335
Baclofen	gamma-Aminobutyric acid-ergic agonist	212
Betaseron		50
Betmiga		26
Botox	Acetylcholine release inhibitor	167
BOTOX Cosmetic	Acetylcholine release inhibitor	59
Bupropion hydrochloride	Aminoketone	36
Celebrex	Nonsteroidal anti-inflammatory drug	29
Chantix	Partial cholinergic nicotinic agonist	46
Cipro	Corticosteroid	50
Ciprofloxacin	Fluoroquinolone antibacterial	190
Citalopram	Serotonin reuptake inhibitor	95
Clonazepam	Benzodiazepine	53
Codeine		31
Copaxone		93
Cosentyx	Interleukin-17A antagonist	99
Crestor	HMG-CoA reductase inhibitor	100
Cymbalta		167
Definity	Contrast agent for ultrasound imaging	43
Desvenlafaxine succinate	Serotonin and norepinephrine reuptake inhibitor	38
Dextroamphet Saccharat Amphet Aspartate Dextroamphet Sulfate and Amphet Sulfat		36
Diazepam	Benzodiazepine	54
Duloxetine	Serotonin and norepinephrine reuptake inhibitor	26
Dupixent	Interleukin-4 receptor alpha antagonist	192
Dysport	Acetylcholine release inhibitor	35
Effexor	Serotonin and norepinephrine reuptake inhibitor	30
Eliquis	Factor Xa inhibitor	52
Enbrel	Tumor necrosis factor blocker	346
Entresto	Angiotensin 2 receptor blocker	43
Epinephrine	Catecholamine	29
Escitalopram	Serotonin reuptake inhibitor	42
Fentanyl	Opioid agonist	56
Fluoxetine	Serotonin reuptake inhibitor	32
Forteo	Parathyroid hormone analog	190
Fosamax	Bisphosphonate	30
Gabapentin	Anti-epileptic agent	94
Gablofen	gamma-Aminobutyric acid-ergic agonist	80
Geodon	Atypical antipsychotic	45
Gilenya	Sphingosine 1-phosphate receptor modulator	202
Humira		427
Ibrance	Kinase inhibitor	39
Ibuprofen	Nonsteroidal anti-inflammatory drug	78
Imbruvica	Kinase inhibitor	40
Imitrex	Serotonin-1b and Serotonin-1d receptor agonist	83
Ingrezza	Vesicular monoamine transporter 2 inhibitor	51
Invega Sustenna	Atypical antipsychotic	25
Jakafi	Janus kinase inhibitor	32
Kesimpta	CD20-directed cytolytic antibody	121
Lamictal	Anti-epileptic agent	41
Lamotrigine	Anti-epileptic agent	31
Latuda	Atypical antipsychotic	58
Levaquin		78
Levofloxacin	Fluoroquinolone antibacterial	135
Levothyroxine		43
Lioresal (baclofen)	gamma-Aminobutyric acid-ergic agonist	250
Lipitor	HMG-CoA reductase inhibitor	122
Lorazepam	Benzodiazepine	35
Lyrica		158
Magnevist		64
Metformin	Biguanide	27
Methotrexate	Folate analog metabolic inhibitor	55
Methylprednisolone sodium succinate	Corticosteroid	33
Metoprolol	beta-Adrenergic blocker	29
Mirena	Progestin	54
Morphine	Opioid agonist	46
MultiHance	Gadolinium-based contrast agent	30
Neurontin		35
Nexium	Proton pump inhibitor	28
Niaspan		31
Ocrevus	CD20-directed cytolytic antibody	165
Olanzapine	Atypical antipsychotic	39
Omalizumab	Anti-IgE	46
Omeprazole	Proton pump inhibitor	34
Omniscan	Paramagnetic contrast agent	39
Opsumit	Endothelin receptor antagonist	44
Optimark		29
Orenitram	Prostacycline vasodilator	33
Otezla	Phosphodiesterase 4 inhibitor	47
Oxaliplatin	Platinum-based drug	32
Pantoprazole	Proton pump inhibitor	26
Paxil	Serotonin reuptake inhibitor	33
Paxlovid		38
Pegasys	Interferon alpha	36
Pomalyst	Thalidomide analog	43
Praluent	PCSK9 inhibitor	47
Prednisone	Corticosteroid	75
Pregabalin		53
ProHance	Paramagnetic contrast agent	29
Prolia	RANK ligand inhibitor	155
Ramipril	Angiotensin converting enzyme inhibitor	65
Rebif	Interferon beta	97
Remicade	Tumor necrosis factor blocker	69
Remodulin	Prostacycline vasodilator	37
Repatha	PCSK9 inhibitor	171
Revlimid	Thalidomide analog	166
Ribavirin	Nucleoside analog antiviral	33
Rinvoq	Janus kinase inhibitor	47
Risperdal	Atypical antipsychotic	40
Risperidone	Atypical antipsychotic	34
Rituxan	CD20-directed cytolytic antibody	25
Rituximab	CD20-directed cytolytic antibody	45
Rytary	Aromatic amino acid	31
Sandostatin LAR Depot		37
Seroquel	Atypical antipsychotic	83
Sertraline	Serotonin reuptake inhibitor	112
Simvastatin	HMG-CoA reductase inhibitor	56
Skyrizi	Interleukin-23 antagonist	37
Soliris	Complement inhibitor	38
Strensiq		25
Sumatriptan	Serotonin-1b and Serotonin-1d receptor agonist	26
Synthroid	l-Thyroxine	36
Tecfidera		281
Tramadol		33
Tymlos		100
Tysabri	Integrin receptor antagonist	472
Tyvaso	Prostacycline vasodilator	30
Uptravi	Prostacyclin receptor agonist	48
Valium	Benzodiazepine	34
Valsartan	Angiotensin 2 receptor blocker	40
Venlafaxine	Serotonin and norepinephrine reuptake inhibitor	38
Venlafaxine hydrochloride	Serotonin and norepinephrine reuptake inhibitor	33
Vivitrol		56
Vyvanse	Central nervous system stimulant	39
Wellbutrin	Aminoketone	31
Xarelto	Factor Xa inhibitor	53
Xeljanz	Janus kinase inhibitor	99
Xolair	Anti-IgE	57
Xyrem	Central nervous system depressant	146
Zoloft	Serotonin reuptake inhibitor	52
Zometa		31
Zyprexa	Atypical antipsychotic	32

The page of each drug has the count of each reaction term in its reaction lookup.

Drug classes in these reports

The table has the 54 pharmacologic classes with 50 or more reports that record this term. The rows are in order of name.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Pharmacologic classes of the drugs that the reports with the term Muscle tightness name, in order of name
Class	Reports with this term
Acetylcholine release inhibitor	280
Aminoketone	104
Angiotensin 2 receptor blocker	133
Angiotensin converting enzyme inhibitor	91
Anti-epileptic agent	193
Anti-IgE	103
Aromatase inhibitor	75
Aromatic amino acid	68
Atypical antipsychotic	729
Benzodiazepine	274
beta-Adrenergic blocker	86
Bisphosphonate	96
Calcium channel blocker	141
CD20-directed cytolytic antibody	370
Central nervous system depressant	180
Central nervous system stimulant	108
Cephalosporin antibacterial	56
Complement inhibitor	58
Corticosteroid	307
Endothelin receptor antagonist	96
Factor Xa inhibitor	111
Fluoroquinolone antibacterial	347
Folate analog metabolic inhibitor	82
Gadolinium-based contrast agent	56
gamma-Aminobutyric acid-ergic agonist	542
GLP-1 receptor agonist	107
HMG-CoA reductase inhibitor	373
Integrin receptor antagonist	496
Interferon beta	467
Interleukin-17A antagonist	110
Interleukin-4 receptor alpha antagonist	199
Interleukin-6 receptor antagonist	75
Janus kinase inhibitor	180
Kinase inhibitor	250
l-Thyroxine	67
Nonsteroidal anti-inflammatory drug	213
Opioid agonist	247
Paramagnetic contrast agent	68
Parathyroid hormone analog	195
PCSK9 inhibitor	218
Potassium channel blocker	171
Progestin	69
Prostacyclin receptor agonist	50
Prostacycline vasodilator	135
Proton pump inhibitor	126
Pyrimidine synthesis inhibitor	93
RANK ligand inhibitor	164
Serotonin and norepinephrine reuptake inhibitor	196
Serotonin reuptake inhibitor	494
Serotonin-1b and Serotonin-1d receptor agonist	165
Sphingosine 1-phosphate receptor modulator	233
Thalidomide analog	223
Tumor necrosis factor blocker	480
Vesicular monoamine transporter 2 inhibitor	57

A class with many reports in all has many reports for almost every term.

Reports by month

Reports that record Muscle tightness, by month, five years to June 2026

FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

Patients in these reports

Age of the patient in the reports that record Muscle tightness
Age	Reports	Share
Under 2	51	0.3%
2 to 11	103	0.6%
12 to 17	165	1%
18 to 44	3,136	19.7%
45 to 64	4,509	28.3%
65 to 74	1,561	9.8%
75 and over	778	4.9%
Age not given	5,602	35.2%

Sex of the patient in the reports that record Muscle tightness
Sex	Reports	Share
Female	10,053	63.2%
Male	4,706	29.6%
Unknown or not given	1,146	7.2%

Age and sex are as the report gives them. 76.4% of these reports give the United States as the country.

Terms near this one

These are the next terms in the A to Z list. The links are for navigation.

Official pages

MedWatch Online Voluntary Reporting FormThe online form of FDA for a voluntary report.
MedWatch: The FDA Safety Information and Adverse Event Reporting ProgramThe page of the FDA program that receives reports about drugs and devices.
FDA Adverse Event Monitoring System (AEMS) Public DashboardThe public dashboard of FDA for adverse event reports on drugs and biologics.

The site checked these addresses on 2 Oct 2026. The links open in a new tab.

Cite this page

Reported Reactions. Muscle tightness: adverse event reports that record this term. https://reportedreactions.com/reaction/muscle-tightness/ Source: U.S. Food and Drug Administration, openFDA Drug Adverse Event (FAERS) files, release of 29 Oct 2026. Reports received through 30 Jun 2026.

Where the data come from

The counts come from the openFDA Drug Adverse Event (FAERS) bulk files, release of 29 Oct 2026. The files have the reports that FDA received through 30 Jun 2026. A drug name is the name on the report. The site matches it to a brand name or a generic name of the National Drug Code Directory of 2 Nov 2026. A class is the pharmacologic class (EPC) of the FDA label.

The count has the reports with each spelling of one MedDRA preferred term. The site does not publish a report narrative, a lot number, a detail of a patient or the identity of a reporter. The record of FDA is the authority. See how the site counts reports, the data sources and the corrections page.

Questions

What does Muscle tightness mean in an adverse event report?

It is a MedDRA preferred term. FDA codes the description of a reporter with the MedDRA dictionary. The openFDA files do not have the description itself, and this site does not show it.

Does a drug in the table mean that the drug was responsible for this reaction?

No. FDA says:

No individual drug is connected to any individual reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

When a report lists multiple drugs and multiple reactions, there is no way to conclude from the data therein that a given drug is responsible for a given reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

What does this page tell a person who has this symptom?

This page gives counts of reports. It cannot assess a person. A pharmacist or a clinician can assess a person.

If this is a medical emergency, please call 911.
Source: FDA, MedWatch Online Voluntary Reporting Form. The site read the page on 2 Oct 2026.

To the top of the page